Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Rosebrock

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.
Nature|May 31, 2019
Growth dynamics in naturally progressing chronic lymphocytic leukaemiaMichaela Gruber, Ivana Bozic, Ignaty Leshchiner, et al.
Nature Genetics|August 22, 2017
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancerPaz Polak, Jaegil Kim, Lior Z Braunstein, et al.
Cancer Cell|August 15, 2018
Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell CarcinomaRaj K Gopal, Kirsten Kübler, Sarah E Calvo, et al.
Nature Communications|October 27, 2017
Resistance to checkpoint blockade therapy through inactivation of antigen presentationMoshe Sade-Feldman, Yunxin J Jiao, Jonathan H Chen, et al.
Nature|January 25, 2023
Author Correction: The evolutionary history of 2,658 cancersMoritz Gerstung, Clemency Jolly, Ignaty Leshchiner, et al.
Nature|February 7, 2020
The evolutionary history of 2,658 cancersMoritz Gerstung, Clemency Jolly, Ignaty Leshchiner, et al.
Cell Reports. Medicine|March 4, 2022
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSamuel S Freeman, Moshe Sade-Feldman, Jaegil Kim, et al.
Cancer Cell|September 24, 2019
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesRomain Guièze, Vivian M Liu, Daniel Rosebrock, et al.
Nature Medicine|June 30, 2018
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.
Nature|May 31, 2019
Growth dynamics in naturally progressing chronic lymphocytic leukaemiaMichaela Gruber, Ivana Bozic, Ignaty Leshchiner, et al.
Nature Genetics|August 22, 2017
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancerPaz Polak, Jaegil Kim, Lior Z Braunstein, et al.
Cancer Cell|August 15, 2018
Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell CarcinomaRaj K Gopal, Kirsten Kübler, Sarah E Calvo, et al.
Nature Communications|October 27, 2017
Resistance to checkpoint blockade therapy through inactivation of antigen presentationMoshe Sade-Feldman, Yunxin J Jiao, Jonathan H Chen, et al.
Nature|January 25, 2023
Author Correction: The evolutionary history of 2,658 cancersMoritz Gerstung, Clemency Jolly, Ignaty Leshchiner, et al.
Nature|February 7, 2020
The evolutionary history of 2,658 cancersMoritz Gerstung, Clemency Jolly, Ignaty Leshchiner, et al.
Cell Reports. Medicine|March 4, 2022
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSamuel S Freeman, Moshe Sade-Feldman, Jaegil Kim, et al.
Cancer Cell|September 24, 2019
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesRomain Guièze, Vivian M Liu, Daniel Rosebrock, et al.
Nature Medicine|June 30, 2018
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Pageof 3